Study provides a snapshot of neurological, psychiatric complications in COVID-19 patients

Clinicians should be alert to the possibility of psychosis, neurocognitive dementia-like syndrome, personality change, mania, anxiety or depression, chronic fatigue syndrome and post-traumatic stress disorder, it says

Corporation health nurse conducts door-to-door checking of coronavirus as a precautionary measure to stop COVID-19, in Thoothukudi on June 27, 2020.

A study of 153 patients treated in U.K. hospitals from April 2 to 26 has found a range of neurological and psychiatric complications that may be linked to COVID-19.

A handful of small studies had earlier reported an association between COVID-19 and possible neurological complications, and a larger one involving 214 patients from Wuhan too have reported such complications in 78 patients.

To investigate the breadth of the complications that affect the brain, researchers set up a secure, U.K.-wide online network for specialist doctors to report details of specific cases. Complete clinical datasets were available for 125 (82%) of the 153 patients, while 114 (92%) of 125 patients with complete notification data had confirmed SARS-CoV-2 infection. The results were published in the journal

The Lancet Psychiatry .

In the U.K. study, a team led by Dr. Benedict Michael from the University of Liverpool found that 62% (77 of 125 people) had broad clinical syndrome of a cerebrovascular event, of whom 57 (74%) had an ischaemic stroke and nine (12%) an intracerebral haemorrhage.

Altered mental status was seen in 31% (39 of 125 people) of the COVID-19 patients. This included nine (23%) patients with unspecified encephalopathy and seven (18%) patients with encephalitis.

The remaining 23 (59%) patients with altered mental status fulfilled the clinical case definitions for psychiatric diagnoses. Psychiatric complications include psychosis, neurocognitive dementia-like syndrome, personality change, catatonia (abnormality of movement and behaviour arising from a disturbed mental state), mania, anxiety or depression, chronic fatigue syndrome, and post-traumatic stress disorder.

Ten (43%) of 23 patients with neuropsychiatric disorders had new-onset psychosis, six (26%) had a neurocognitive (dementia-like) syndrome and four (17%) had mood disorder.

“Altered mental status (defined as an acute alteration in personality, behaviour, cognition, or consciousness) was identified across all age groups, and many (49%) younger patients had this presentation,” they write. In contrast, cerebrovascular events were seen more in people older than 60 years (82%, 61 of 74 patients) while only 18% (13 of 74 patients) were younger than 60 years.

According to the authors, altered mental status is “common in patients admitted to hospital with severe infection, especially in those requiring intensive care management”. However, this is typically seen in older people and might reflect an “unmasking of latent neurocognitive degenerative disease or multiple medical comorbidities”.

“Clinicians should be alert to the possibility of patients with COVID-19 developing these complications and, conversely, of the possibility of COVID-19 in patients presenting with acute neurological and psychiatric syndromes,” they write.

The authors caution that the link between COVID-19 and new acute psychiatric or neuropsychiatric complications in younger patients will require detailed prospective longitudinal studies.

They caution that the “rates of neurological and psychiatric complications of COVID-19 cannot be extrapolated to mildly affected patients or patients with asymptomatic infection, especially those in the community.”

But they also say the true extent of neurological or psychiatric symptoms may be an underestimate considering that many COVID-19 patients are managed in an ICU with sedative and paralytic medications, which can mask and contribute to complications caused by treatment. The cohort studied might “under-represent patients with milder outpatient symptoms, such as reduced taste or smell”, they write.